2,5-Dimethoxy-4-ethylthioamphetamine

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
2,5-Dimethoxy-4-ethylthioamphetamine
Accession Number
DB13940
Type
Small Molecule
Groups
Experimental
Description

2,5-Dimethoxy-4-ethylthioamphetamine (ALEPH-2) is a phenylisopropylamine derivative with alleged anxiolytic and hallucinogenic properties.

Structure
Thumb
Synonyms
  • 2,5-Dimethoxy-4-ethylthioamphetamine
  • 4-(Ethylthio)-2,5-dimethoxy-alpha-methylbenzeneethanamine
  • ALEPH-2
Categories
UNII
Z1I419DRZZ
CAS number
185562-00-9
Weight
Average: 255.38
Monoisotopic: 255.129300094
Chemical Formula
C13H21NO2S
InChI Key
MCYCODJKXUJSAT-UHFFFAOYSA-N
InChI
InChI=1S/C13H21NO2S/c1-5-17-13-8-11(15-3)10(6-9(2)14)7-12(13)16-4/h7-9H,5-6,14H2,1-4H3
IUPAC Name
1-[4-(ethylsulfanyl)-2,5-dimethoxyphenyl]propan-2-amine
SMILES
CCSC1=CC(OC)=C(CC(C)N)C=C1OC

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
TargetActionsOrganism
U5-hydroxytryptamine receptor 2A
agonist
Human
U5-hydroxytryptamine receptor 2C
agonist
Human
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
7,8-Dichloro-1,2,3,4-tetrahydroisoquinolineThe risk or severity of adverse effects can be increased when 2,5-Dimethoxy-4-ethylthioamphetamine is combined with 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.Experimental
AcepromazineAcepromazine may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylthioamphetamine.Approved, Vet Approved
AceprometazineAceprometazine may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylthioamphetamine.Approved
AcetazolamideAcetazolamide may decrease the excretion rate of 2,5-Dimethoxy-4-ethylthioamphetamine which could result in a higher serum level.Approved, Vet Approved
AcetophenazineAcetophenazine may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylthioamphetamine.Approved
Acrivastine2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative activities of Acrivastine.Approved
Alcaftadine2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative activities of Alcaftadine.Approved
Alfentanil2,5-Dimethoxy-4-ethylthioamphetamine may increase the analgesic activities of Alfentanil.Approved, Illicit
Alimemazine2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative activities of Alimemazine.Approved, Vet Approved
AlmasilateAlmasilate may decrease the excretion rate of 2,5-Dimethoxy-4-ethylthioamphetamine which could result in a higher serum level.Approved, Experimental
AloglutamolAloglutamol may decrease the excretion rate of 2,5-Dimethoxy-4-ethylthioamphetamine which could result in a higher serum level.Approved
Alphacetylmethadol2,5-Dimethoxy-4-ethylthioamphetamine may increase the analgesic activities of Alphacetylmethadol.Experimental, Illicit
Alphaprodine2,5-Dimethoxy-4-ethylthioamphetamine may increase the analgesic activities of Alphaprodine.Illicit
AluminiumAluminium may decrease the excretion rate of 2,5-Dimethoxy-4-ethylthioamphetamine which could result in a higher serum level.Approved, Investigational
Aluminium acetoacetateAluminium acetoacetate may decrease the excretion rate of 2,5-Dimethoxy-4-ethylthioamphetamine which could result in a higher serum level.Experimental
Aluminium glycinateAluminium glycinate may decrease the excretion rate of 2,5-Dimethoxy-4-ethylthioamphetamine which could result in a higher serum level.Experimental
Aluminum hydroxideAluminum hydroxide may decrease the excretion rate of 2,5-Dimethoxy-4-ethylthioamphetamine which could result in a higher serum level.Approved, Investigational
AmineptineAmineptine may increase the stimulatory activities of 2,5-Dimethoxy-4-ethylthioamphetamine.Illicit, Withdrawn
AmisulprideAmisulpride may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylthioamphetamine.Approved, Investigational
AmitriptylineAmitriptyline may increase the stimulatory activities of 2,5-Dimethoxy-4-ethylthioamphetamine.Approved
AmitriptylinoxideAmitriptylinoxide may increase the stimulatory activities of 2,5-Dimethoxy-4-ethylthioamphetamine.Approved, Investigational
Ammonium chlorideThe serum concentration of 2,5-Dimethoxy-4-ethylthioamphetamine can be decreased when it is combined with Ammonium chloride.Approved, Investigational, Vet Approved
AmoxapineAmoxapine may increase the stimulatory activities of 2,5-Dimethoxy-4-ethylthioamphetamine.Approved
AmperozideAmperozide may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylthioamphetamine.Experimental
AmphetamineThe risk or severity of adverse effects can be increased when 2,5-Dimethoxy-4-ethylthioamphetamine is combined with Amphetamine.Approved, Illicit, Investigational
Antazoline2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative activities of Antazoline.Approved
AripiprazoleAripiprazole may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylthioamphetamine.Approved, Investigational
AsenapineAsenapine may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylthioamphetamine.Approved
Astemizole2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative activities of Astemizole.Approved, Withdrawn
AzaperoneAzaperone may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylthioamphetamine.Investigational, Vet Approved
Azatadine2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative activities of Azatadine.Approved
Azelastine2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative activities of Azelastine.Approved
Bamipine2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative activities of Bamipine.Experimental
BenmoxinThe risk or severity of adverse effects can be increased when 2,5-Dimethoxy-4-ethylthioamphetamine is combined with Benmoxin.Withdrawn
BenperidolBenperidol may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylthioamphetamine.Approved, Investigational
Benzatropine2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative activities of Benzatropine.Approved
Bezitramide2,5-Dimethoxy-4-ethylthioamphetamine may increase the analgesic activities of Bezitramide.Experimental, Illicit, Withdrawn
BifeprunoxBifeprunox may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylthioamphetamine.Investigational
Bismuth SubcitrateBismuth Subcitrate may decrease the excretion rate of 2,5-Dimethoxy-4-ethylthioamphetamine which could result in a higher serum level.Approved, Investigational
Bismuth subnitrateBismuth subnitrate may decrease the excretion rate of 2,5-Dimethoxy-4-ethylthioamphetamine which could result in a higher serum level.Approved
BrexpiprazoleBrexpiprazole may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylthioamphetamine.Approved, Investigational
BrofaromineThe risk or severity of adverse effects can be increased when 2,5-Dimethoxy-4-ethylthioamphetamine is combined with Brofaromine.Experimental
BromperidolBromperidol may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylthioamphetamine.Approved, Investigational
Brompheniramine2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative activities of Brompheniramine.Approved
Buclizine2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative activities of Buclizine.Approved
Buprenorphine2,5-Dimethoxy-4-ethylthioamphetamine may increase the analgesic activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
ButaperazineButaperazine may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylthioamphetamine.Experimental
Butorphanol2,5-Dimethoxy-4-ethylthioamphetamine may increase the analgesic activities of Butorphanol.Approved, Illicit, Vet Approved
ButriptylineButriptyline may increase the stimulatory activities of 2,5-Dimethoxy-4-ethylthioamphetamine.Approved
Butyric Acid2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative activities of Butyric Acid.Experimental, Investigational
Calcium CarbonateCalcium Carbonate may decrease the excretion rate of 2,5-Dimethoxy-4-ethylthioamphetamine which could result in a higher serum level.Approved, Investigational
Calcium silicateCalcium silicate may decrease the excretion rate of 2,5-Dimethoxy-4-ethylthioamphetamine which could result in a higher serum level.Experimental
Carbinoxamine2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative activities of Carbinoxamine.Approved
Carfentanil2,5-Dimethoxy-4-ethylthioamphetamine may increase the analgesic activities of Carfentanil.Illicit, Investigational, Vet Approved
CariprazineCariprazine may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylthioamphetamine.Approved, Investigational
CaroxazoneThe risk or severity of adverse effects can be increased when 2,5-Dimethoxy-4-ethylthioamphetamine is combined with Caroxazone.Withdrawn
Cetirizine2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative activities of Cetirizine.Approved
Chloropyramine2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative activities of Chloropyramine.Approved
Chlorphenamine2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative activities of Chlorphenamine.Approved
Chlorphenoxamine2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative activities of Chlorphenoxamine.Withdrawn
ChlorproethazineChlorproethazine may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylthioamphetamine.Experimental
ChlorpromazineChlorpromazine may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylthioamphetamine.Approved, Investigational, Vet Approved
ChlorprothixeneChlorprothixene may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylthioamphetamine.Approved, Investigational, Withdrawn
Cimetidine2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative activities of Cimetidine.Approved, Investigational
Cinnarizine2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative activities of Cinnarizine.Approved, Investigational
Clemastine2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative activities of Clemastine.Approved, Investigational
ClomipramineClomipramine may increase the stimulatory activities of 2,5-Dimethoxy-4-ethylthioamphetamine.Approved, Investigational, Vet Approved
ClopenthixolClopenthixol may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylthioamphetamine.Experimental
ClothiapineClothiapine may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylthioamphetamine.Experimental
ClozapineClozapine may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylthioamphetamine.Approved
Codeine2,5-Dimethoxy-4-ethylthioamphetamine may increase the analgesic activities of Codeine.Approved, Illicit
CyamemazineCyamemazine may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylthioamphetamine.Approved
Cyclizine2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative activities of Cyclizine.Approved
Cyproheptadine2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative activities of Cyproheptadine.Approved
DapiprazoleDapiprazole may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylthioamphetamine.Approved
DesipramineDesipramine may increase the stimulatory activities of 2,5-Dimethoxy-4-ethylthioamphetamine.Approved, Investigational
Desloratadine2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative activities of Desloratadine.Approved, Investigational
Dexbrompheniramine2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative activities of Dexbrompheniramine.Approved
Dexchlorpheniramine2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative activities of Dexchlorpheniramine.Experimental, Investigational
Dexchlorpheniramine maleate2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative activities of Dexchlorpheniramine maleate.Approved
Dextromoramide2,5-Dimethoxy-4-ethylthioamphetamine may increase the analgesic activities of Dextromoramide.Experimental, Illicit
Dextropropoxyphene2,5-Dimethoxy-4-ethylthioamphetamine may increase the analgesic activities of Dextropropoxyphene.Approved, Illicit, Investigational, Withdrawn
Dezocine2,5-Dimethoxy-4-ethylthioamphetamine may increase the analgesic activities of Dezocine.Approved, Investigational
DibenzepinDibenzepin may increase the stimulatory activities of 2,5-Dimethoxy-4-ethylthioamphetamine.Experimental
DiclofenamideDiclofenamide may decrease the excretion rate of 2,5-Dimethoxy-4-ethylthioamphetamine which could result in a higher serum level.Approved, Investigational
Dihydrocodeine2,5-Dimethoxy-4-ethylthioamphetamine may increase the analgesic activities of Dihydrocodeine.Approved, Illicit
Dihydroetorphine2,5-Dimethoxy-4-ethylthioamphetamine may increase the analgesic activities of Dihydroetorphine.Experimental, Illicit
Dihydromorphine2,5-Dimethoxy-4-ethylthioamphetamine may increase the analgesic activities of Dihydromorphine.Experimental, Illicit
Dimenhydrinate2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative activities of Dimenhydrinate.Approved
DimetacrineDimetacrine may increase the stimulatory activities of 2,5-Dimethoxy-4-ethylthioamphetamine.Approved, Withdrawn
Dimetindene2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative activities of Dimetindene.Approved, Investigational
Dimetotiazine2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative activities of Dimetotiazine.Approved
Diphenhydramine2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative activities of Diphenhydramine.Approved, Investigational
Diphenoxylate2,5-Dimethoxy-4-ethylthioamphetamine may increase the analgesic activities of Diphenoxylate.Approved, Illicit
DixyrazineDixyrazine may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylthioamphetamine.Experimental
DosulepinDosulepin may increase the stimulatory activities of 2,5-Dimethoxy-4-ethylthioamphetamine.Approved
Doxepin2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative activities of Doxepin.Approved, Investigational
Doxylamine2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative activities of Doxylamine.Approved, Vet Approved
DPDPE2,5-Dimethoxy-4-ethylthioamphetamine may increase the analgesic activities of DPDPE.Experimental
DroperidolDroperidol may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylthioamphetamine.Approved, Vet Approved
Ebastine2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative activities of Ebastine.Approved, Investigational
EcopipamEcopipam may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylthioamphetamine.Investigational
Emedastine2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative activities of Emedastine.Approved
Epinastine2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative activities of Epinastine.Approved, Investigational
Esmirtazapine2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative activities of Esmirtazapine.Investigational
Ethopropazine2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative activities of Ethopropazine.Approved
Ethosuximide2,5-Dimethoxy-4-ethylthioamphetamine can cause a decrease in the absorption of Ethosuximide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
EthoxzolamideEthoxzolamide may decrease the excretion rate of 2,5-Dimethoxy-4-ethylthioamphetamine which could result in a higher serum level.Withdrawn
Ethylmorphine2,5-Dimethoxy-4-ethylthioamphetamine may increase the analgesic activities of Ethylmorphine.Approved, Illicit
Etorphine2,5-Dimethoxy-4-ethylthioamphetamine may increase the analgesic activities of Etorphine.Illicit, Vet Approved
Famotidine2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative activities of Famotidine.Approved
FencamfamineFencamfamine may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylthioamphetamine.Approved, Illicit, Withdrawn
Fentanyl2,5-Dimethoxy-4-ethylthioamphetamine may increase the analgesic activities of Fentanyl.Approved, Illicit, Investigational, Vet Approved
Fexofenadine2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative activities of Fexofenadine.Approved, Investigational
FluanisoneFluanisone may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylthioamphetamine.Experimental
Flunarizine2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative activities of Flunarizine.Approved
FlupentixolFlupentixol may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylthioamphetamine.Approved, Investigational, Withdrawn
FluphenazineFluphenazine may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylthioamphetamine.Approved
FluspirileneFluspirilene may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylthioamphetamine.Approved, Investigational
FurazolidoneThe risk or severity of adverse effects can be increased when 2,5-Dimethoxy-4-ethylthioamphetamine is combined with Furazolidone.Approved, Investigational, Vet Approved
Glutamic AcidThe serum concentration of 2,5-Dimethoxy-4-ethylthioamphetamine can be decreased when it is combined with Glutamic Acid.Approved, Nutraceutical
GuanethidineThe serum concentration of 2,5-Dimethoxy-4-ethylthioamphetamine can be decreased when it is combined with Guanethidine.Approved
HaloperidolHaloperidol may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylthioamphetamine.Approved
HarmalineThe risk or severity of adverse effects can be increased when 2,5-Dimethoxy-4-ethylthioamphetamine is combined with Harmaline.Experimental
Heroin2,5-Dimethoxy-4-ethylthioamphetamine may increase the analgesic activities of Heroin.Approved, Illicit, Investigational
HydracarbazineThe risk or severity of adverse effects can be increased when 2,5-Dimethoxy-4-ethylthioamphetamine is combined with Hydracarbazine.Experimental
Hydrocodone2,5-Dimethoxy-4-ethylthioamphetamine may increase the analgesic activities of Hydrocodone.Approved, Illicit
Hydromorphone2,5-Dimethoxy-4-ethylthioamphetamine may increase the analgesic activities of Hydromorphone.Approved, Illicit
HydrotalciteHydrotalcite may decrease the excretion rate of 2,5-Dimethoxy-4-ethylthioamphetamine which could result in a higher serum level.Approved, Experimental, Investigational
Hydroxyzine2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative activities of Hydroxyzine.Approved
IloperidoneIloperidone may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylthioamphetamine.Approved
ImipramineImipramine may increase the stimulatory activities of 2,5-Dimethoxy-4-ethylthioamphetamine.Approved
Ioflupane I-1232,5-Dimethoxy-4-ethylthioamphetamine may decrease effectiveness of Ioflupane I-123 as a diagnostic agent.Approved
IprindoleIprindole may increase the stimulatory activities of 2,5-Dimethoxy-4-ethylthioamphetamine.Experimental
IproclozideThe risk or severity of adverse effects can be increased when 2,5-Dimethoxy-4-ethylthioamphetamine is combined with Iproclozide.Withdrawn
IproniazidThe risk or severity of adverse effects can be increased when 2,5-Dimethoxy-4-ethylthioamphetamine is combined with Iproniazid.Withdrawn
IsocarboxazidThe risk or severity of adverse effects can be increased when 2,5-Dimethoxy-4-ethylthioamphetamine is combined with Isocarboxazid.Approved
Isothipendyl2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative activities of Isothipendyl.Approved
Ketobemidone2,5-Dimethoxy-4-ethylthioamphetamine may increase the analgesic activities of Ketobemidone.Approved, Investigational
Ketotifen2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative activities of Ketotifen.Approved
Lafutidine2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative activities of Lafutidine.Investigational
Lavoltidine2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative activities of Lavoltidine.Investigational
Levocabastine2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative activities of Levocabastine.Approved, Investigational
Levocetirizine2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative activities of Levocetirizine.Approved
Levomethadyl Acetate2,5-Dimethoxy-4-ethylthioamphetamine may increase the analgesic activities of Levomethadyl Acetate.Approved, Investigational
Levorphanol2,5-Dimethoxy-4-ethylthioamphetamine may increase the analgesic activities of Levorphanol.Approved
LithiumLithium may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylthioamphetamine.Approved
Lodoxamide2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative activities of Lodoxamide.Approved
Lofentanil2,5-Dimethoxy-4-ethylthioamphetamine may increase the analgesic activities of Lofentanil.Illicit
LofepramineLofepramine may increase the stimulatory activities of 2,5-Dimethoxy-4-ethylthioamphetamine.Experimental
Loratadine2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative activities of Loratadine.Approved, Investigational
LoxapineLoxapine may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylthioamphetamine.Approved
LurasidoneLurasidone may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylthioamphetamine.Approved, Investigational
MagaldrateMagaldrate may decrease the excretion rate of 2,5-Dimethoxy-4-ethylthioamphetamine which could result in a higher serum level.Approved, Withdrawn
Magnesium hydroxideMagnesium hydroxide may decrease the excretion rate of 2,5-Dimethoxy-4-ethylthioamphetamine which could result in a higher serum level.Approved, Investigational
Magnesium oxideMagnesium oxide may decrease the excretion rate of 2,5-Dimethoxy-4-ethylthioamphetamine which could result in a higher serum level.Approved
Magnesium peroxideMagnesium peroxide may decrease the excretion rate of 2,5-Dimethoxy-4-ethylthioamphetamine which could result in a higher serum level.Experimental
Magnesium silicateMagnesium silicate may decrease the excretion rate of 2,5-Dimethoxy-4-ethylthioamphetamine which could result in a higher serum level.Approved
Magnesium TrisilicateMagnesium Trisilicate may decrease the excretion rate of 2,5-Dimethoxy-4-ethylthioamphetamine which could result in a higher serum level.Approved
MebanazineThe risk or severity of adverse effects can be increased when 2,5-Dimethoxy-4-ethylthioamphetamine is combined with Mebanazine.Withdrawn
Meclizine2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative activities of Meclizine.Approved
MelitracenMelitracen may increase the stimulatory activities of 2,5-Dimethoxy-4-ethylthioamphetamine.Experimental, Investigational
MelperoneMelperone may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylthioamphetamine.Approved, Investigational
Meptazinol2,5-Dimethoxy-4-ethylthioamphetamine may increase the analgesic activities of Meptazinol.Experimental
Mepyramine2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative activities of Mepyramine.Approved, Vet Approved
Mequitazine2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative activities of Mequitazine.Approved
MesoridazineMesoridazine may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylthioamphetamine.Approved, Investigational
Methadone2,5-Dimethoxy-4-ethylthioamphetamine may increase the analgesic activities of Methadone.Approved
Methadyl Acetate2,5-Dimethoxy-4-ethylthioamphetamine may increase the analgesic activities of Methadyl Acetate.Approved, Illicit
Methapyrilene2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative activities of Methapyrilene.Withdrawn
MethazolamideMethazolamide may decrease the excretion rate of 2,5-Dimethoxy-4-ethylthioamphetamine which could result in a higher serum level.Approved
MethenamineThe serum concentration of 2,5-Dimethoxy-4-ethylthioamphetamine can be decreased when it is combined with Methenamine.Approved, Vet Approved
MethotrimeprazineMethotrimeprazine may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylthioamphetamine.Approved, Investigational
Methylene blueThe risk or severity of adverse effects can be increased when 2,5-Dimethoxy-4-ethylthioamphetamine is combined with Methylene blue.Approved, Investigational
Metiamide2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative activities of Metiamide.Experimental
Mianserin2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative activities of Mianserin.Approved, Investigational
MinaprineThe risk or severity of adverse effects can be increased when 2,5-Dimethoxy-4-ethylthioamphetamine is combined with Minaprine.Approved
Mirtazapine2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative activities of Mirtazapine.Approved
Mizolastine2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative activities of Mizolastine.Investigational
MoclobemideThe risk or severity of adverse effects can be increased when 2,5-Dimethoxy-4-ethylthioamphetamine is combined with Moclobemide.Approved, Investigational
MolindoneMolindone may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylthioamphetamine.Approved
MoperoneMoperone may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylthioamphetamine.Experimental
Morphine2,5-Dimethoxy-4-ethylthioamphetamine may increase the analgesic activities of Morphine.Approved, Investigational
MosapramineMosapramine may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylthioamphetamine.Experimental
Nalbuphine2,5-Dimethoxy-4-ethylthioamphetamine may increase the analgesic activities of Nalbuphine.Approved
NialamideThe risk or severity of adverse effects can be increased when 2,5-Dimethoxy-4-ethylthioamphetamine is combined with Nialamide.Withdrawn
Nicomorphine2,5-Dimethoxy-4-ethylthioamphetamine may increase the analgesic activities of Nicomorphine.Experimental
Nizatidine2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative activities of Nizatidine.Approved
Normethadone2,5-Dimethoxy-4-ethylthioamphetamine may increase the analgesic activities of Normethadone.Approved, Illicit
NortriptylineNortriptyline may increase the stimulatory activities of 2,5-Dimethoxy-4-ethylthioamphetamine.Approved
OctamoxinThe risk or severity of adverse effects can be increased when 2,5-Dimethoxy-4-ethylthioamphetamine is combined with Octamoxin.Withdrawn
OlanzapineOlanzapine may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylthioamphetamine.Approved, Investigational
Olopatadine2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative activities of Olopatadine.Approved
OndansetronOndansetron may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylthioamphetamine.Approved
OpipramolOpipramol may increase the stimulatory activities of 2,5-Dimethoxy-4-ethylthioamphetamine.Investigational
Opium2,5-Dimethoxy-4-ethylthioamphetamine may increase the analgesic activities of Opium.Approved, Illicit
OsanetantOsanetant may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylthioamphetamine.Investigational
Oxatomide2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative activities of Oxatomide.Investigational
Oxycodone2,5-Dimethoxy-4-ethylthioamphetamine may increase the analgesic activities of Oxycodone.Approved, Illicit, Investigational
Oxymorphone2,5-Dimethoxy-4-ethylthioamphetamine may increase the analgesic activities of Oxymorphone.Approved, Investigational, Vet Approved
OxypertineOxypertine may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylthioamphetamine.Experimental
Ozagrel2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative activities of Ozagrel.Investigational
PaliperidonePaliperidone may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylthioamphetamine.Approved
PargylineThe risk or severity of adverse effects can be increased when 2,5-Dimethoxy-4-ethylthioamphetamine is combined with Pargyline.Approved
Pemirolast2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative activities of Pemirolast.Approved, Investigational
PenfluridolPenfluridol may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylthioamphetamine.Experimental
Pentazocine2,5-Dimethoxy-4-ethylthioamphetamine may increase the analgesic activities of Pentazocine.Approved, Vet Approved
PerazinePerazine may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylthioamphetamine.Approved, Investigational
PerospironePerospirone may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylthioamphetamine.Approved
PerphenazinePerphenazine may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylthioamphetamine.Approved
Pethidine2,5-Dimethoxy-4-ethylthioamphetamine may increase the analgesic activities of Pethidine.Approved
Phenazocine2,5-Dimethoxy-4-ethylthioamphetamine may increase the analgesic activities of Phenazocine.Experimental
PhenelzineThe risk or severity of adverse effects can be increased when 2,5-Dimethoxy-4-ethylthioamphetamine is combined with Phenelzine.Approved
Phenindamine2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative activities of Phenindamine.Approved
PheniprazineThe risk or severity of adverse effects can be increased when 2,5-Dimethoxy-4-ethylthioamphetamine is combined with Pheniprazine.Withdrawn
Pheniramine2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative activities of Pheniramine.Approved
PhenobarbitalThe serum concentration of Phenobarbital can be decreased when it is combined with 2,5-Dimethoxy-4-ethylthioamphetamine.Approved, Investigational
Phenoperidine2,5-Dimethoxy-4-ethylthioamphetamine may increase the analgesic activities of Phenoperidine.Experimental
PhenoxypropazineThe risk or severity of adverse effects can be increased when 2,5-Dimethoxy-4-ethylthioamphetamine is combined with Phenoxypropazine.Withdrawn
PhenytoinThe serum concentration of Phenytoin can be decreased when it is combined with 2,5-Dimethoxy-4-ethylthioamphetamine.Approved, Vet Approved
PimozidePimozide may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylthioamphetamine.Approved
PipamperonePipamperone may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylthioamphetamine.Approved, Investigational
PipotiazinePipotiazine may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylthioamphetamine.Approved, Investigational
Piritramide2,5-Dimethoxy-4-ethylthioamphetamine may increase the analgesic activities of Piritramide.Approved, Investigational
PirlindoleThe risk or severity of adverse effects can be increased when 2,5-Dimethoxy-4-ethylthioamphetamine is combined with Pirlindole.Approved
PivhydrazineThe risk or severity of adverse effects can be increased when 2,5-Dimethoxy-4-ethylthioamphetamine is combined with Pivhydrazine.Withdrawn
ProcarbazineThe risk or severity of adverse effects can be increased when 2,5-Dimethoxy-4-ethylthioamphetamine is combined with Procarbazine.Approved, Investigational
ProchlorperazineProchlorperazine may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylthioamphetamine.Approved, Vet Approved
PromazinePromazine may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylthioamphetamine.Approved, Vet Approved
Promethazine2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative activities of Promethazine.Approved, Investigational
PropericiazinePropericiazine may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylthioamphetamine.Approved, Investigational
ProthipendylProthipendyl may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylthioamphetamine.Investigational
ProtriptylineProtriptyline may increase the stimulatory activities of 2,5-Dimethoxy-4-ethylthioamphetamine.Approved
QuetiapineQuetiapine may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylthioamphetamine.Approved
Quifenadine2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative activities of Quifenadine.Experimental
RacloprideRaclopride may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylthioamphetamine.Investigational
Ranitidine2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative activities of Ranitidine.Approved
RasagilineThe risk or severity of adverse effects can be increased when 2,5-Dimethoxy-4-ethylthioamphetamine is combined with Rasagiline.Approved
Remifentanil2,5-Dimethoxy-4-ethylthioamphetamine may increase the analgesic activities of Remifentanil.Approved
RemoxiprideRemoxipride may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylthioamphetamine.Approved, Withdrawn
ReserpineReserpine may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylthioamphetamine.Approved, Investigational
RisperidoneRisperidone may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylthioamphetamine.Approved, Investigational
RitanserinRitanserin may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylthioamphetamine.Investigational
Roxatidine acetate2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative activities of Roxatidine acetate.Approved, Investigational
SafrazineThe risk or severity of adverse effects can be increased when 2,5-Dimethoxy-4-ethylthioamphetamine is combined with Safrazine.Withdrawn
SelegilineThe risk or severity of adverse effects can be increased when 2,5-Dimethoxy-4-ethylthioamphetamine is combined with Selegiline.Approved, Investigational, Vet Approved
SertindoleSertindole may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylthioamphetamine.Approved, Investigational, Withdrawn
Sodium bicarbonateSodium bicarbonate may decrease the excretion rate of 2,5-Dimethoxy-4-ethylthioamphetamine which could result in a higher serum level.Approved
Sufentanil2,5-Dimethoxy-4-ethylthioamphetamine may increase the analgesic activities of Sufentanil.Approved, Investigational
SulpirideSulpiride may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylthioamphetamine.Approved, Investigational
SultoprideSultopride may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylthioamphetamine.Experimental
Tapentadol2,5-Dimethoxy-4-ethylthioamphetamine may increase the analgesic activities of Tapentadol.Approved
Terfenadine2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative activities of Terfenadine.Approved, Withdrawn
Tesmilifene2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative activities of Tesmilifene.Investigational
TetrahydropalmatineTetrahydropalmatine may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylthioamphetamine.Investigational
ThiopropazateThiopropazate may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylthioamphetamine.Experimental
ThioproperazineThioproperazine may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylthioamphetamine.Approved
ThioridazineThioridazine may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylthioamphetamine.Approved, Withdrawn
ThiothixeneThiothixene may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylthioamphetamine.Approved
Thonzylamine2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative activities of Thonzylamine.Approved
TianeptineTianeptine may increase the stimulatory activities of 2,5-Dimethoxy-4-ethylthioamphetamine.Approved, Investigational
TiaprideTiapride may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylthioamphetamine.Approved, Investigational
Tilidine2,5-Dimethoxy-4-ethylthioamphetamine may increase the analgesic activities of Tilidine.Experimental
ToloxatoneThe risk or severity of adverse effects can be increased when 2,5-Dimethoxy-4-ethylthioamphetamine is combined with Toloxatone.Approved
Tramadol2,5-Dimethoxy-4-ethylthioamphetamine may increase the analgesic activities of Tramadol.Approved, Investigational
Tranilast2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative activities of Tranilast.Approved, Investigational
TranylcypromineThe risk or severity of adverse effects can be increased when 2,5-Dimethoxy-4-ethylthioamphetamine is combined with Tranylcypromine.Approved, Investigational
TrifluoperazineTrifluoperazine may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylthioamphetamine.Approved, Investigational
TrifluperidolTrifluperidol may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylthioamphetamine.Experimental
TriflupromazineTriflupromazine may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylthioamphetamine.Approved, Vet Approved
TrimipramineTrimipramine may increase the stimulatory activities of 2,5-Dimethoxy-4-ethylthioamphetamine.Approved
Tripelennamine2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative activities of Tripelennamine.Approved, Vet Approved
Triprolidine2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative activities of Triprolidine.Approved
Tritoqualine2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative activities of Tritoqualine.Experimental
TromethamineTromethamine may decrease the excretion rate of 2,5-Dimethoxy-4-ethylthioamphetamine which could result in a higher serum level.Approved
VeraliprideVeralipride may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylthioamphetamine.Experimental
Vitamin CThe serum concentration of 2,5-Dimethoxy-4-ethylthioamphetamine can be decreased when it is combined with Vitamin C.Approved, Nutraceutical
ZiprasidoneZiprasidone may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylthioamphetamine.Approved
ZotepineZotepine may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylthioamphetamine.Approved, Investigational, Withdrawn
ZuclopenthixolZuclopenthixol may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylthioamphetamine.Approved, Investigational
Food Interactions
Not Available

References

General References
Not Available
External Links
ChemSpider
8439835
BindingDB
50164337
ChEMBL
CHEMBL339611

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.267 mg/mLALOGPS
logP2.9ALOGPS
logP2.37ChemAxon
logS-3ALOGPS
pKa (Strongest Basic)9.91ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area44.48 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity74.19 m3·mol-1ChemAxon
Polarizability29.15 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Classification
Not classified

Targets

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Agonist
General Function
Virus receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodop...
Gene Name
HTR2A
Uniprot ID
P28223
Uniprot Name
5-hydroxytryptamine receptor 2A
Molecular Weight
52602.58 Da
References
  1. Acuna-Castillo C, Scorza C, Reyes-Parada M, Cassels BK, Huidobro-Toro JP: ALEPH-2, a suspected anxiolytic and putative hallucinogenic phenylisopropylamine derivative, is a 5-HT2a and 5-HT2c receptor agonist. Life Sci. 2000 Nov 17;67(26):3241-7. [PubMed:11191631]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Agonist
General Function
Serotonin receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including ergot alkaloid derivatives, 1-2,5,-dimethoxy-4-...
Gene Name
HTR2C
Uniprot ID
P28335
Uniprot Name
5-hydroxytryptamine receptor 2C
Molecular Weight
51820.705 Da
References
  1. Acuna-Castillo C, Scorza C, Reyes-Parada M, Cassels BK, Huidobro-Toro JP: ALEPH-2, a suspected anxiolytic and putative hallucinogenic phenylisopropylamine derivative, is a 5-HT2a and 5-HT2c receptor agonist. Life Sci. 2000 Nov 17;67(26):3241-7. [PubMed:11191631]

Drug created on December 31, 2017 20:29 / Updated on May 02, 2018 00:41